Dr. Joudrey is an Assistant Professor in the Division of General Internal Medicine at the University of Pittsburgh School of Medicine. He provides primary care, addiction medicine, and harm reduction services within outpatient and community settings. His research focuses on identifying factors impacting addiction treatment access and outcomes across urban and rural communities and developing, evaluating, and scaling interventions tailored to community needs to improve the health of people who use drugs. This includes research to expand access to patient centered methadone treatment for opioid use disorder.
He is Co-lead Investigator for NIDA CTN-131, a randomized pragmatic trial of office-based methadone versus buprenorphine. He received his undergraduate degree from Case Western Reserve University and his medical degree from New York University. Dr. Joudrey completed residency training at Montefiore Medical Center in the Primary Care Social Internal Medicine program and completed the National Clinician Scholars Program fellowship at Yale School of Medicine.
Dr. Joudrey grew up on his family’s apple orchard and farm market near Mansfield, Ohio. He and his sister, Anne Joudrey, co-founded North Central Ohio Harm Reduction to improve the health of people who use drugs in North Central Ohio.
Education & Training
- BA (Biology), Case Western Reserve University, 2005
- MEd (Secondary Science Education), City College of New York, 2009
- MD, New York University, 2014
- MPH (Global Public Health), New York University, 2014
- MHS (Health Services Research), Yale School of Medicine, 2019
- Internal Medicine Residency, Montefiore Medical Center Primary Care Social Internal Medicine Program, 2017
- Fellowship, National Clinician Scholars Program, Internal Medicine, Yale University School of Medicine, 2019
Representative Publications
Joudrey PJ, Edelman EJ, Wang EA. Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States. JAMA. 2019 Oct 1;322(13):1310-1312.
Drive time to the nearest opioid treatment program increased within crease rural county classification. This urban-rural disparity could be mitigated with methadone prescribing within Federally Qualified Health Centers.
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020 Mar 27;211:107968.
The urban-rural disparity in drive time to the nearest opioid treatment program could be mitigated with methadone dispensing within community pharmacies.
Joudrey PJ, Adams ZM, Bach P, Van Buren S, Chaiton JA, Ehrenfeld L, Guerra ME, Gleeson B, Kimmel SD, Medley A, Mekideche W, Paquet M, Sung M, Wang M, You Kheang ROO, Zhang J, Wang EA, Edelman EJ. Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. JAMA Netw Open. 2021 Jul 1;4(7):e2118223.
Methadone availability may be worse than previously estimated and the shortage was exacerbated by COVID-19. Canadian clinics provide timelier access than US opioid treatment programs.
Joudrey PJ, Kolak M, Lin Q, Paykin S, Anguiano V Jr, Wang EA. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. JAMA Netw Open. 2022 Apr 1;5(4):e227028.
Communities with greater social vulnerability did not have greater geographic access to medications, and the mismatch was greatest in suburban communities. Rural communities had poor geographic access regardless of vulnerability.
Click here for a more complete bibliography of Dr. Joudrey’s works
Research Interests
- Improving equity in access to methadone for opioid use disorder across rural and urban communities
- Addressing differences in access to medications for opioid use disorder across urban and rural communities
- Promoting adoption of evidence-based treatment for unhealthy alcohol use in general medical settings